Clinical Evidence for Wegovy Weight Loss Despite Constipation
Understanding Constipation on Wegovy: UK Clinical Trial Evidence
Constipation on Wegovy occurs in approximately 24% of patients according to the STEP clinical trial programme, making it one of the most frequently reported gastrointestinal side effects alongside nausea and diarrhoea. However, this shouldn't overshadow the significant weight loss results demonstrated in UK and international studies. The mechanism behind constipation relates to Wegovy's action as a GLP-1 receptor agonist, which slows gastric emptying and affects gut motility as part of its appetite-regulating function.
What's encouraging for UK patients is that constipation on Wegovy typically emerges during the initial dose escalation phase and often improves as the body adapts to treatment. Clinical data shows that most gastrointestinal side effects, including constipation, are usually mild to moderate in severity and transient in nature. At EverydayMeds, our prescribing team monitors patients closely during the critical first 16 weeks of dose escalation, ensuring any constipation concerns are addressed promptly while maintaining the weight loss trajectory demonstrated in clinical trials.
Wegovy Weight Loss Results: UK Pricing and Clinical Value
Despite potential constipation concerns, Wegovy delivers exceptional weight loss results that justify the treatment investment for eligible UK patients. Starting at £79.99 for the 0.25mg starter dose (with code FIRST40), the medication has demonstrated consistent efficacy across multiple clinical trials. The STEP 1 trial, published by Wilding et al. in NEJM 2021, showed that patients taking Wegovy alongside diet and exercise achieved an average clinically studied weight loss at 68 weeks, compared to just 2.4% with placebo.
Our bundle pricing structure supports patients through the entire dose escalation journey, with the Intro Trio (0.25mg, 0.5mg, and 1mg) available for £299.99, covering the first 12 weeks of treatment. For patients reaching maintenance therapy, the 2.4mg dose costs £209.99, representing excellent value when considering the sustained weight loss results. Returning customers benefit from code DOSE25 applied at checkout, whilst our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, ensuring treatment continuity even if constipation requires temporary dose adjustments.
STEP Trial Evidence: Constipation Rates vs Weight Loss Outcomes
The comprehensive STEP clinical trial programme provides reassuring data for UK patients concerned about constipation on Wegovy. While 24% of patients experienced constipation, the majority continued treatment and achieved significant weight loss results. STEP 1 demonstrated ~15% average weight loss, STEP 3 showed ~16% with intensive behavioural therapy, and STEP 5 confirmed ~15.2% sustained weight loss at two years.
Most importantly, the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, suggesting that the health benefits of Wegovy extend far beyond weight loss alone. These findings indicate that managing constipation on Wegovy is worthwhile given the substantial metabolic and cardiovascular improvements achievable through sustained treatment.
How Wegovy Works: GLP-1 Mechanism and Digestive Effects
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and gastric emptying. This mechanism explains why constipation on Wegovy occurs – the medication deliberately slows food movement through the digestive system, promoting satiety after smaller meals. The same mechanism that reduces appetite and supports weight loss can temporarily disrupt normal bowel patterns, particularly during the initial weeks of treatment. Understanding this connection helps patients recognise that constipation, while uncomfortable, indicates the medication is working as intended. With proper hydration, dietary fibre, and gradual dose escalation, most patients successfully manage this side effect whilst achieving their weight loss goals.
EverydayMeds Ordering Process: Clinical Assessment and Delivery
Our streamlined ordering process ensures patients experiencing constipation on Wegovy receive appropriate clinical oversight from day one. The 3-minute online clinical assessment specifically enquires about gastrointestinal health and previous constipation issues, allowing our prescribers to provide tailored advice before treatment begins. Standard prescriber review takes 3 working days, though patients with urgent concerns about side effects can request express 24-hour review. Once approved, all Wegovy orders are dispatched via next-day delivery using temperature-controlled cold-chain logistics, ensuring medication potency regardless of weather conditions. Our GPhC-registered pharmacy (#9012878) maintains comprehensive patient records, enabling ongoing monitoring and support throughout your weight loss journey.
Storage and Practical Considerations During Side Effect Management
Proper Wegovy storage becomes particularly important when managing constipation, as treatment interruptions can disrupt both weight loss progress and digestive adaptation. Store unused pens in the fridge at 2-8°C, though Wegovy can survive up to 6 weeks at room temperature below 30°C once removed from refrigeration – a significant advantage over competitors requiring constant refrigeration. The FlexTouch pen design simplifies weekly injections even during periods of digestive discomfort. Mandatory dose escalation from 0.25mg through to 2.4mg maintenance allows gradual digestive adaptation, reducing the severity of constipation compared to starting at higher doses. Never skip doses or extend intervals beyond 7 days, as this can worsen gastrointestinal side effects when resuming treatment.
UK-Specific Constipation Management During Wegovy Treatment
British patients experiencing constipation on Wegovy benefit from NHS guidance recommending increased fluid intake, dietary fibre, and gentle exercise – strategies that complement weight loss goals. Unlike other countries where expensive specialist consultations may be required, UK patients can access free GP advice for managing medication-related constipation. EverydayMeds works collaboratively with NHS healthcare providers, sharing relevant clinical information to ensure comprehensive care.
Our clinical team recognises that UK dietary patterns, including lower baseline fibre intake compared to Mediterranean diets, may predispose patients to constipation when starting Wegovy. We provide culturally appropriate dietary advice, suggesting practical modifications to traditional British meals that support both digestive health and weight loss objectives. This integrated approach helps patients achieve the weight loss results demonstrated in clinical trials whilst minimising treatment disruption from side effects.
Long-term Success: Maintaining Weight Loss Results Despite Early Constipation
Clinical evidence strongly supports persisting with Wegovy treatment despite initial constipation concerns, given the sustained weight loss benefits achievable with consistent use. The STEP 5 trial demonstrated that patients maintaining Wegovy treatment achieved ~clinically studied weight loss at two years, whilst those who discontinued treatment regained approximately two-thirds of lost weight within one year. This data emphasises that temporary digestive side effects shouldn't derail long-term weight management goals.
At EverydayMeds, we support patients through the critical first 16 weeks when constipation on Wegovy is most likely to occur, providing practical management strategies and clinical reassurance. Our Elevate Trio bundle (1mg, 1.7mg, and 2.4mg) for £499.99 covers weeks 9-20+, the crucial period when digestive adaptation typically occurs and weight loss results become most evident. With proper support and persistence, the vast majority of patients successfully navigate early side effects and achieve the life-changing weight loss results demonstrated in clinical trials. Start your journey today using code FIRST40 for new customers or DOSE25 for returning patients, backed by our comprehensive clinical support throughout treatment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
